title: MAGE-specific cytotoxic T lymphocytes require non-specific CD54 adherence receptors on carcinoma cells.
abstract: We investigated several factors that could regulate the susceptibility of carcinoma cells to MAGE-2-specific CTL mediated lysis. Cytofluorometric analysis showed that the cytolysis correlated with the expression of CD54. IFN-gamma treatment induced the TAP-1 and LMP-2 genes, continuously up-regulated the HLA class I expression and increased cytolysis. Although HLA class I were highly induced in MRKnu1 cells, CD54 was not induced and the cytolysis was minimal. Cytotolysis of IFN-gamma-treated MKN-1 cells was completely inhibited by a monoclonal anti-CD54 antibody. These results suggest that HLA-restricted CTL lysis requires non-specific CD54 adherence receptors in addition to specific TCR signals.
authors.affiliation: Department of Surgery I, Oita Medical University, Oita 879-5593, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tahara
authors.forename: N
authors.initials: N
authors.lastname: Sadanaga
authors.forename: H
authors.initials: H
authors.lastname: Nagashima
authors.forename: S
authors.initials: S
authors.lastname: Kitano
authors.forename: M
authors.initials: M
authors.lastname: Mori
mesh_terms: D000071181:ATP Binding Cassette Transporter, Subfamily B, Member 2; D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D015703:Antigens, CD / Q000187:drug effects / Q000378:metabolism; D000951:Antigens, Neoplasm; D000954:Antigens, Surface / Q000187:drug effects / Q000378:metabolism; D018122:B7-1 Antigen / Q000187:drug effects / Q000378:metabolism; D051940:B7-2 Antigen; D003546:Cysteine Endopeptidases; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D015234:HLA-A Antigens / Q000276:immunology; D059871:HLA-A24 Antigen; D015395:Histocompatibility Antigens Class I / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D007371:Interferon-gamma / Q000494:pharmacology; D020014:K562 Cells; D008562:Membrane Glycoproteins / Q000187:drug effects / Q000378:metabolism; D009363:Neoplasm Proteins / Q000276:immunology*; D011506:Proteins / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology*; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000276:immunology; D015854:Up-Regulation; D019014:fas Receptor / Q000187:drug effects / Q000378:metabolism
chemical_list: D000071181:ATP Binding Cassette Transporter, Subfamily B, Member 2; D018528:ATP-Binding Cassette Transporters; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D018122:B7-1 Antigen; D051940:B7-2 Antigen; C497964:CD86 protein, human; D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D015395:Histocompatibility Antigens Class I; C072012:MAGEB2 protein, human; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D011506:Proteins; C073119:TAP1 protein, human; D019014:fas Receptor; D018799:Intercellular Adhesion Molecule-1; C071313:LMP-2 protein; D007371:Interferon-gamma; D003546:Cysteine Endopeptidases